Published in

Future Medicine, Future Oncology, 4(18), p. 445-455, 2022

DOI: 10.2217/fon-2021-0332

Links

Tools

Export citation

Search in Google Scholar

Risk of second primary malignancies associated with radiotherapy in prostate cancer patients: competing risk analysis

Journal article published in 2022 by Yijun Wu ORCID, Yunlong Li ORCID, Chang Han, Yuming Chong, Kai Kang, Zhikai Liu, Fuquan Zhang
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Background: The effect of radiotherapy (RT) for second primary malignancies (SPMs) among prostate cancer survivors is controversial. Methods: Applying logistic regression, competing risk analysis and propensity score matching method, this study analyzed clinical data from the Surveillance, Epidemiology, and End Results program to compare the risk for SPMs between patients receiving RT and non-RT. Results: In this study, prostate cancer patients treated with RT developed more SPMs in the anus, bladder, rectum, liver, lung and bronchus and lymphoma than non-RT groups. Conclusion: More intensive surveillance should be adopted for these cancers among prostate cancer survivors.